Abstract
Data on cellular immunity of 39 patients with breast cancer and 29 patients with malignant melanoma, is presented. T/B lymphocyte ratios, lymphocyte blastogenesis (LB) with PHA and with cancer antigen preparations were carried out from two to four weeks after cancer surgery, and immediately after eight weeks of immunostimulation with a tumor-specific vaccine. Distinct differences were observed. Small breast cancers do not seem to evoke a host immune response, while small melanomas are associated with a state of immune stimulation. After immunotherapy LB in these breast cancer patients shows significant stimulation while LB in the melanoma patients changed from stimulation to normal response. Quite different results were obtained in patients with Stage II cancers; breast cancer patients showed immune stimulation which did not change after immunotherapy. The melanoma patients showed low normal immune response, which changed to high normal after immunotherapy. Patients with Stage III breast cancer and melanoma were similar in their poor immune responsiveness. Possible mechanisms are offered for these differences.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Böyum A. Isolation of leucocytes from human blood. Further observations. Methylcellulose, dextran, and ficoll as erythrocyteaggregating agents. Scand J Clin Lab Invest Suppl. 1968;97:31–50. [PubMed] [Google Scholar]
- Fujimoto S., Greene M. I., Sehon A. H. Regulation of the immune response to tumor antigens. II. The nature of immunosuppressor cells in tumor-bearing hosts. J Immunol. 1976 Mar;116(3):800–806. [PubMed] [Google Scholar]
- Hilal E. Y., Wanebo H. J., Pinsky C. M., Middleman P., Strong E. W., Oettgen H. F. Immunologic evaluation and prognosis in patients with head and neck cancer. Am J Surg. 1977 Oct;134(4):468–473. doi: 10.1016/0002-9610(77)90380-4. [DOI] [PubMed] [Google Scholar]
- Humphrey L. J., Singla O., Volenec F. J. Immunologic responsiveness of the breast cancer patient. Cancer. 1980 Aug 15;46(4 Suppl):893–898. doi: 10.1002/1097-0142(19800815)46:4+<893::aid-cncr2820461307>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
- Irvin G. L., 3rd, Eustace J. C., McAleer J. A., Levi D. F. A study of tumor allograft sensitized lymph nodes in mice. II. In vitro immunoglobulin synthesis, immunofluorescence and morphology. J Immunol. 1972 Jan;108(1):207–213. [PubMed] [Google Scholar]
- Jewell W. R., Thomas J. H., Sterchi J. M., Morse P. A., Humphrey L. J. Critical analysis of treatment of stage II and stage III melanoma patients with immunotherapy. Ann Surg. 1976 May;183(5):543–549. doi: 10.1097/00000658-197605000-00011. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Jondal M., Holm G., Wigzell H. Surface markers on human T and B lymphocytes. I. A large population of lymphocytes forming nonimmune rosettes with sheep red blood cells. J Exp Med. 1972 Aug 1;136(2):207–215. doi: 10.1084/jem.136.2.207. [DOI] [PMC free article] [PubMed] [Google Scholar]
- LAMB D., PILNEY F., KELLY W. D., GOOD R. A. A comparative study of the incidence of anergy in patients with carcinoma, leukemia, hodgkin's disease and other lymphomas. J Immunol. 1962 Oct;89:555–558. [PubMed] [Google Scholar]
- Morton D. L., Eilber F. R., Holmes E. C., Hunt J. S., Ketcham A. S., Silverstein M. J., Sparks F. C. BCG immunotherapy of malignant melanoma: summary of a seven-year experience. Ann Surg. 1974 Oct;180(4):635–643. doi: 10.1097/00000658-197410000-00029. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wood G. W., Volenec F. J., Mani M. M., Humphrey L. J. Dynamics of T-lymphocyte subpopulations and T-lymphocyte function following thermal injury. Clin Exp Immunol. 1978 Feb;31(2):291–297. [PMC free article] [PubMed] [Google Scholar]
- Wybran J., Belohradsky B. H., Fudenberg H. H. Unmasking by antimetabolites of receptors for sheep red blood cells on human lymphocytes. Cell Immunol. 1974 Dec;14(3):359–365. doi: 10.1016/0008-8749(74)90185-3. [DOI] [PubMed] [Google Scholar]